Stryker (SYK) Expected to Announce Quarterly Earnings on Thursday

Stryker (NYSE:SYK) is expected to announce its Q1 2025 earnings results after the market closes on Thursday, May 1st. Analysts expect the company to announce earnings of $2.76 per share and revenue of $5.68 billion for the quarter.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the firm earned $3.46 EPS. On average, analysts expect Stryker to post $13 EPS for the current fiscal year and $15 EPS for the next fiscal year.

Stryker Stock Performance

Shares of SYK stock opened at $370.92 on Wednesday. The business has a fifty day moving average of $367.06 and a 200 day moving average of $373.49. Stryker has a 1 year low of $314.93 and a 1 year high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a market capitalization of $141.58 billion, a price-to-earnings ratio of 47.80, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.91%. Stryker’s dividend payout ratio is currently 43.30%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on SYK shares. Wells Fargo & Company upped their price objective on shares of Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Argus set a $450.00 price target on shares of Stryker in a report on Monday, February 3rd. Citigroup reiterated a “buy” rating and set a $450.00 price objective on shares of Stryker in a research note on Wednesday, February 26th. JPMorgan Chase & Co. upped their target price on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Finally, Stifel Nicolaus lifted their price target on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average target price of $423.53.

Insider Buying and Selling

In related news, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Stryker stock. Brighton Jones LLC lifted its position in shares of Stryker Co. (NYSE:SYK) by 15.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,564 shares of the medical technology company’s stock after purchasing an additional 609 shares during the period. Brighton Jones LLC’s holdings in Stryker were worth $1,643,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.